Story perspectives

Caribou Biosciences Shuts Down After Lymphoma Trial Funding Failure

By Drooid · Oct 7, 2026, 7:57 PM UTC · How we work

Summary

Story summary

Caribou Biosciences is shutting down after it could not raise funding for a late-stage lymphoma trial.
CEO Rachel Haurwitz told STAT the company failed to secure financing for the study.
The firm will discontinue development of its two CRISPR-based CAR-T therapies.
One therapy, vispa-cel, was designed for advanced B-cell non-Hodgkin lymphoma.
Caribou, based in Berkeley, California, had worked with the FDA on the Phase 3 design for vispa-cel.

1 of 1

Story summary

Caribou Biosciences is shutting down after it could not raise funding for a late-stage lymphoma trial.
CEO Rachel Haurwitz told STAT the company failed to secure financing for the study.
The firm will discontinue development of its two CRISPR-based CAR-T therapies.
One therapy, vispa-cel, was designed for advanced B-cell non-Hodgkin lymphoma.
Caribou, based in Berkeley, California, had worked with the FDA on the Phase 3 design for vispa-cel.